Status:
UNKNOWN
ASsessment of Adherence TO Medication in AtRIAl Fibrillation - an eMonitoring Drug Dispensing Device Study
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
Pilloxa
Conditions:
Adherence, Patient
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The ASTORIA study is a prospective cohort single-armed multicenter observational study that aims to assess adherence to rivaroxaban using a high technological electronical pillbox connected to a phone...
Eligibility Criteria
Inclusion
- Female or male patient with age \> 18 years
- Patients with atrial fibrillation
- Patients initiated, continued on or switched to rivaroxaban for the indication atrial fibrillation with intended lifelong treatment (CHA2 DS2-VASc score ≥ 1).
- The patient must agree to the use of the electronic medication adherence monitoring device, the so-called Pilloxa box and need to have a sufficient understanding of the app and functionality in conjunction with the use of the Pilloxa box.
- Signed informed consent
- No participation in an investigational program with interventions outside of routine clinical practice
- No contra-indications according to the local marketing authorization
Exclusion
- Participation in an investigational program with interventions outside of routine clinical practice
- Contra-indications according to the local marketing authorization
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04815161
Start Date
June 1 2022
End Date
August 1 2023
Last Update
May 24 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.